About
Products
Knolens
KnolScapes
Knolens
Knolens SLR
Knolens
KnolQuest
Knolens
Edge
Knolens
DataNexus
Platform
Solutions
KnolSights
Experience Knolens
Columvi Extends Overall Survival in Relapsed/Refractory DLBCL Patients: Two-Year Follow-up Data
Roche announced two-year follow-up data from the Phase III STARGLO study, showing a 40% improvement in overall survival (OS) for patients with relapse...
Copyright © 2025. All rights reserved
About
Terms of Service
Privacy Policy
Home/
KnloSights/
Clinical Trial Updates/
Columvi Extends Overall Survival in Relapsed/Refractory DLBCL Patients: Two-Year Follow-up Data